Phase II evaluation of menogaril in women with metastatic breast cancer after failure of first-line chemotherapy

H. J. Long, Daniel J Schaid, A. J. Schutt, J. N. Ingle, Charles Lawrence Loprinzi, J. H. Edmonson

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

A total of 25 patients with metastatic breast cancer who had failed one prior chemotherapy regimen and had not received prior treatment with doxorubicin were treated with menogaril (200 mg/m2 i.v. over 1 h) every 4 weeks. Four patients (16%) achieved partial regressions lasting a median of 46 days. The median survival was 264 days. Seventeen patients subsequently received doxorubicin after removal from protocol and six (35%) achieved objective regression. We conclude that menogaril administered by the method that we employed has marginal activity in women with metastatic breast cancer after failure of prior chemotherapy. Failure to respond to menogaril does not preclude response to subsequent treatment with doxorubicin.

Original languageEnglish (US)
Pages (from-to)524-527
Number of pages4
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume11
Issue number5
StatePublished - 1988

Fingerprint

Menogaril
Doxorubicin
Breast Neoplasms
Drug Therapy
Survival
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Phase II evaluation of menogaril in women with metastatic breast cancer after failure of first-line chemotherapy. / Long, H. J.; Schaid, Daniel J; Schutt, A. J.; Ingle, J. N.; Loprinzi, Charles Lawrence; Edmonson, J. H.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 11, No. 5, 1988, p. 524-527.

Research output: Contribution to journalArticle

@article{a172fc058b0a4d0ab947b68abb4086a9,
title = "Phase II evaluation of menogaril in women with metastatic breast cancer after failure of first-line chemotherapy",
abstract = "A total of 25 patients with metastatic breast cancer who had failed one prior chemotherapy regimen and had not received prior treatment with doxorubicin were treated with menogaril (200 mg/m2 i.v. over 1 h) every 4 weeks. Four patients (16{\%}) achieved partial regressions lasting a median of 46 days. The median survival was 264 days. Seventeen patients subsequently received doxorubicin after removal from protocol and six (35{\%}) achieved objective regression. We conclude that menogaril administered by the method that we employed has marginal activity in women with metastatic breast cancer after failure of prior chemotherapy. Failure to respond to menogaril does not preclude response to subsequent treatment with doxorubicin.",
author = "Long, {H. J.} and Schaid, {Daniel J} and Schutt, {A. J.} and Ingle, {J. N.} and Loprinzi, {Charles Lawrence} and Edmonson, {J. H.}",
year = "1988",
language = "English (US)",
volume = "11",
pages = "524--527",
journal = "American Journal of Clinical Oncology: Cancer Clinical Trials",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Phase II evaluation of menogaril in women with metastatic breast cancer after failure of first-line chemotherapy

AU - Long, H. J.

AU - Schaid, Daniel J

AU - Schutt, A. J.

AU - Ingle, J. N.

AU - Loprinzi, Charles Lawrence

AU - Edmonson, J. H.

PY - 1988

Y1 - 1988

N2 - A total of 25 patients with metastatic breast cancer who had failed one prior chemotherapy regimen and had not received prior treatment with doxorubicin were treated with menogaril (200 mg/m2 i.v. over 1 h) every 4 weeks. Four patients (16%) achieved partial regressions lasting a median of 46 days. The median survival was 264 days. Seventeen patients subsequently received doxorubicin after removal from protocol and six (35%) achieved objective regression. We conclude that menogaril administered by the method that we employed has marginal activity in women with metastatic breast cancer after failure of prior chemotherapy. Failure to respond to menogaril does not preclude response to subsequent treatment with doxorubicin.

AB - A total of 25 patients with metastatic breast cancer who had failed one prior chemotherapy regimen and had not received prior treatment with doxorubicin were treated with menogaril (200 mg/m2 i.v. over 1 h) every 4 weeks. Four patients (16%) achieved partial regressions lasting a median of 46 days. The median survival was 264 days. Seventeen patients subsequently received doxorubicin after removal from protocol and six (35%) achieved objective regression. We conclude that menogaril administered by the method that we employed has marginal activity in women with metastatic breast cancer after failure of prior chemotherapy. Failure to respond to menogaril does not preclude response to subsequent treatment with doxorubicin.

UR - http://www.scopus.com/inward/record.url?scp=0023786434&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023786434&partnerID=8YFLogxK

M3 - Article

C2 - 2972192

AN - SCOPUS:0023786434

VL - 11

SP - 524

EP - 527

JO - American Journal of Clinical Oncology: Cancer Clinical Trials

JF - American Journal of Clinical Oncology: Cancer Clinical Trials

SN - 0277-3732

IS - 5

ER -